Chang et al., 1998 - Google Patents
Arginase modulates nitric oxide production in activated macrophagesChang et al., 1998
View HTML- Document ID
- 17658098090000140648
- Author
- Chang C
- Liao J
- Kuo L
- Publication year
- Publication venue
- American Journal of Physiology-Heart and Circulatory Physiology
External Links
Snippet
In macrophages and many other cell types, l-arginine is used as a substrate by both nitric oxide synthase (NOS) and arginase to produce nitric oxide (NO) and urea, respectively. Because the availability ofl-arginine is a major determinant for NO synthesis in the activated …
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 O=[N] 0 title abstract description 302
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang et al. | Arginase modulates nitric oxide production in activated macrophages | |
| Akhigbe et al. | The impact of reactive oxygen species in the development of cardiometabolic disorders: a review | |
| Taylor et al. | Inducible nitric oxide synthase in the liver: regulation and function | |
| Liu et al. | The antioxidative function of alpha‐ketoglutarate and its applications | |
| Singh et al. | Nitric oxide, the biological mediator of the decade: fact or fiction? | |
| Chowanadisai et al. | Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1α expression | |
| Ajamieh et al. | Effects of ozone oxidative preconditioning on nitric oxide generation and cellular redox balance in a rat model of hepatic ischaemia–reperfusion | |
| Chang et al. | Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity | |
| Dai et al. | Nitric oxide and energy metabolism in mammals | |
| Chen et al. | Identification of the enzymatic mechanism of nitroglycerin bioactivation | |
| Han et al. | Antioxidant enzymes suppress nitric oxide production through the inhibition of NF-κB activation: role of H2O2 and nitric oxide in inducible nitric oxide synthase expression in macrophages | |
| Yang et al. | What has passed is prolog: new cellular and physiological roles of G6PD | |
| Olson et al. | Activation of hypoxia-inducible factor-1 protects airway epithelium against oxidant-induced barrier dysfunction | |
| Teshima et al. | Regulation of growth and apoptosis of cultured guinea pig gastric mucosal cells by mitogenic oxidase 1 | |
| Zang et al. | Cardiac mitochondrial damage and loss of ROS defense after burn injury: the beneficial effects of antioxidant therapy | |
| Zeng et al. | Hepatic hepcidin protects against polymicrobial sepsis in mice by regulating host iron status | |
| Satarug et al. | Evidence for a synergistic interaction between cadmium and endotoxin toxicity and for nitric oxide and cadmium displacement of metals in the kidney | |
| Kwon et al. | Niacin and selenium attenuate sepsis-induced lung injury by up-regulating nuclear factor erythroid 2–related factor 2 signaling | |
| Worrall et al. | INHIBITION OF INDUCIBLE NITRIC OXIDE SYNTHASE AMELIORATES FUNCTIONAL AND HISTOLOGICAL CHANGES OF ACUTE LUNG ALLOGRAFT REJECTION1, 2 | |
| Potenza et al. | Immunoregulatory effects of L-arginine and therapeutical implications | |
| Mathuria et al. | Ameliorative effect of curcumin on aflatoxin-induced toxicity in serum of mice | |
| Shatanawi et al. | Plasma arginase activity is elevated in type 2 diabetic patients | |
| Pacheco-Yepez et al. | Peroxynitrite and peroxiredoxin in the pathogenesis of experimental amebic liver abscess | |
| Milbourne et al. | Does nitric oxide play a role in liver function? | |
| Van Gammeren et al. | Diaphragmatic nitric oxide synthase is not induced during mechanical ventilation |